LDL-C水平与口服阿托伐他汀对颅内动脉瘤Pipeline治疗结局的影响
基于SESIA登记研究,纳入2018至2022年中国4中心1193例Pipeline装置植入患者,比较阿托伐他汀20 mg/日使用者与匹配的非使用者。匹配队列中他汀降低围手术期脑血管并发症(2.0% vs 8.5%)和随访缺血并发症(1.7% vs 5.1%);基线LDL-C≥2.59 mmol/L者获益更显著。
要点
- 他汀降低围手术期脑血管并发症(2.0% vs 8.5%,P=0.001)
- 他汀降低随访缺血事件(1.7% vs 5.1%,P=0.020)
- 基线LDL-C≥2.59 mmol/L患者他汀获益更显著
核心结论
- 阿托伐他汀治疗通过减少缺血事件改善Pipeline装置植入后结局,基线LDL-C升高者获益更明显。
- 该人群辅助他汀治疗的长期获益仍需进一步研究。
研究设计与样本
- 基于SESIA登记研究(NCT03387995),纳入2018至2022年中国4中心接受Pipeline装置植入的1193例患者(53.75±11.07岁,69.4%女性)。
- 他汀使用者(阿托伐他汀20 mg/日,术前≥3天、术后≥6个月)与非使用者按1:1倾向性评分匹配,并采用逆概率治疗加权进一步调整。
- 随访3至48个月,结局包括围手术期并发症、动脉瘤闭塞、支架内狭窄及末次随访临床预后。
主要发现
- 匹配队列(352对)中,他汀组围手术期脑血管并发症发生率为2.0%,非他汀组为8.5%(P=0.001)。
- 匹配队列中,他汀组随访缺血并发症发生率为1.7%,非他汀组为5.1%(P=0.020)。
- 基线LDL-C≥2.59 mmol/L者中,他汀与围手术期脑血管并发症减少相关(OR 0.371,95%CI 0.195-0.705,P=0.002)。
- 基线LDL-C≥2.59 mmol/L者中,他汀与支架内狭窄减少相关(HR 0.433,95%CI 0.269-0.698,P=0.001),与随访缺血事件减少相关(HR 0.315,95%CI 0.135-0.733,P=0.007)。
- 匹配后分析证实围手术期脑血管并发症(OR 0.416,95%CI 0.211-0.821)、支架内狭窄(HR 0.397,95%CI 0.232-0.667)和随访缺血事件(HR 0.364,95%CI 0.148-0.895)结果一致。
关键数值与推荐
- 他汀使用定义为阿托伐他汀20 mg每日一次,术前至少3天、术后至少6个月。
- 基线LDL-C分层界值为2.59 mmol/L。
- 围手术期脑血管并发症交互作用P=0.671,支架内狭窄交互作用P=0.009,随访缺血事件交互作用P=0.507(与<2.59 mmol/L比较)。
临床怎么用
- 颅内动脉瘤Pipeline治疗围手术期可考虑使用阿托伐他汀20 mg/日以降低缺血并发症。
- 基线LDL-C≥2.59 mmol/L的患者可能从他汀治疗中获益更显著。
局限性
- 原文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine the effects of statin treatment on outcomes of pipeline embolization device therapy for intracranial aneurysms in relation to LDL (low-density lipoprotein) cholesterol levels. METHODS: Using data from the SESIA registry (Safety and Efficacy of Stent Deployment for Intracranial Aneurysms), we enrolled participants who underwent pipeline embolization device implantation at 4 centers in China (2018-2022). Statin users (atorvastatin 20 mg daily, for ≥3 days and ≥6 months preprocedurally and postprocedurally, respectively) were matched with nonstatin users (1:1) using propensity scores and further adjusted by inverse probability of treatment weighting, balancing for baseline characteristics, procedural details, and lipid levels (based on East Asian profiles). Study outcomes include perioperative complications, aneurysmal occlusion, in-stent stenosis, and clinical prognosis at the latest follow-up. Multivariable analyses using logistic and Cox regression models adjusted for these factors in both prematched and postmatched cohorts, evaluating the role of lipid modification in subgroups. RESULTS: Of the 1558 patients screened, 1193 (53.75±11.07 years, 69.4% females; statin: n=603, nonstatin: n=590) were enrolled with 3- to 48-month follow-up. In the matched cohort (352 pairs), statin treatment reduced the incidences of perioperative cerebrovascular (2.0% versus 8.5%, P=0.001) and follow-up ischemic (1.7% versus 5.1%, P=0.020) complications. Multivariable analyses in participants with baseline LDL-cholesterol ≥2.59 mmol/L showed that statin treatment was associated with fewer perioperative cerebrovascular complications (odds ratio, 0.371 [95% CI, 0.195-0.705]; P=0.002), in-stent stenosis (hazard ratio, 0.433 [95% CI, 0.269-0.698]; P=0.001), and follow-up ischemic events (hazard ratio, 0.315 [95% CI, 0.135-0.733]; P=0.007; P values for interaction were 0.671, 0.009, and 0.507, respectively, versus <2.59 mmol/L). Postmatched analyses confirmed consistency for perioperative cerebrovascular complications (odds ratio, 0.416 [95% CI, 0.211-0.821]), in-stent stenosis (hazard ratio, 0.397 [95% CI, 0.232-0.667]), and follow-up ischemic events (hazard ratio, 0.364 [95% CI, 0.148-0.895]). CONCLUSIONS: Atorvastatin treatment improved postpipeline embolization device-deployment outcomes by reducing ischemic events, particularly in patients with elevated LDL-cholesterol. The long-term benefits of adjunctive statin use in this population warrant further investigation. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03387995.
引用
- Feng X, Huang C, Tong X, et al. Effect of LDL-Cholesterol Levels and Oral Atorvastatin on Outcomes After Pipeline Therapy for Intracranial Aneurysms. Stroke. 2025. PMID: 40765506. doi:10.1161/STROKEAHA.124.049833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。